In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin)

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 6, 2006, Pages 811-818

  Ryu, Jung Su ^a,c   Lee, Hong Sub ^a   Hong, Young Soo ^b   Lee, Jung Joon ^b   Sohn, Uy Dong ^c   Kim, Tae Yong ^a  

^a ILDONG Pharmaceutical Co   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Chung Ang University   (South Korea)

Author keywords

Anthracycline; Cardiotoxicity; Hyrubicin; ID6105; Xenograft

Indexed keywords

11 HYDROXYACLACINOMYCIN X; ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; GEMCITABINE; HYRUBICIN; ID 6105; LIPID; MITOMYCIN C; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CANCER REGRESSION; CANCER SIZE; CARDIOTOXICITY; CELL STRAIN; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HEART MUSCLE CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LUNG CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT;

ACLARUBICIN; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; FEMALE; HEART; HUMANS; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED BALB C; MYOCARDIUM; NUCLEIC ACID SYNTHESIS INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645732326     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0118-0     Document Type: Article

References (23)

1. Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, Manzini S, Supino R, Zunino F (1997) New developments in antitumor anthracyclines. Pharmacol Ther 76:117-124
2. Aubel-Sadron G, Londos-Gagliardi D (1984) Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 66:333-352
3. Deffie AM, Batra JK, Goldenberg GJ (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49:58-62
4. Di Marco A, Gaetani M, Scarpinato B (1969) Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep 53:33-37
5. Di Marco A, Lenaz L, Casazza AM, Scarpinato BM (1972) Activity of adriamycin (NSC-123127) and daunomycin (NSC-82151) against mouse mammary carcinoma. Cancer Chemother Rep 56: 153-161
6. Doroshow JH (1983) Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43:460-472
7. Forrest GL, Gonzalez B, Tseng W, Li X, Mann J (2000) Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 60:5158-5164
8. Friedman MA, Bozdech MJ, Billingham ME, Rider AK (1978) Doxorubicin cardiotoxicity Serial endomyocardial biopsies and systolic time intervals. JAMA 240:1603-1606
9. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741
10. Hwang CK, Kim HS, Hong YS, Kim YH, Hong SK, Kim SJ, Lee JJ (1995) Expression of Streptomyces peucetius genes for doxorubicin resistance and aklavinone 11-hydroxylase in Streptomyces galilaeus ATCC 31133 and production of a hybrid aclacinomycin. Antimicrob Agents Chemother 39:1616-1620
11. Jain D (2000) Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 7:53-62
12. Kim HS, Hong YS, Kim YH, Yoo OJ, Lee JJ (1996) New anthracycline metabolites produced by the aklavinone 11-hydroxylase gene in Streptomyces galilaeus ATCC 31133. J Antibiot (Tokyo) 49:355-360
13. Kim HS, Kim YH, Yoo OJ, Lee JJ (1996) Aclacinomycin X, a novel anthracycline antibiotic produced by Streptomyces galilaeus ATCC 31133. Biosci Biotechnol Biochem 60:906-908
14. Mason JW, Bristow MR, Billingham ME, Daniels JR (1978) Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62:857-864
15. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT (1999) Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 25:237-247
16. Monneret C (2001) Recent developments in the field of antitumour anthracyclines. Eur J Med Chem 36:483-493
17. Oki T (1977) New anthracycline antibiotics. Jpn J Antibiot 30(Suppl):70-84
18. Singal PK, Iliskovic N, Li T, Kumar D (1997) Adriamycin cardiomyopathy: pathophysiology and prevention. Faseb J 11:931-936
19. Trevor W. Swearman MI (1997) Anthracyclines. In: Teicher BA (ed) Cancer therapeutic: experimental and clinical agents. Human Press, pp 113-136
20. Von Hoff DD, Rozencweig M, Piccart M (1982) The cardiotoxicity of anticancer agents. Semin Oncol 9:23-33
21. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB (2001) Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 61:771-777
22. Zunino F, Gambetta R, Di Marco A, Zaccara A (1972) Interaction of daunomycin and its derivatives with DNA. Biochim Biophys Acta 277:489-498
23. Zunino F, Pratesi G, Perego P (2001) Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs. Biochem Pharmacol 61:933-938